Targeted STING Activation Using Modified Ultrasound‐Responsive Microbubbles Enhances Immune Checkpoint Blockade Against Melanoma
Advanced Science · 2025
DOI: 10.1002/advs.202416596 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Sina Khorsandi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Microbubbles, Melanoma, Immunotherapy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Texas Southwestern Medical Center, U.S. Department of Defense, American Cancer Society Research Scholar.
Abstract (Originalsprache)
Despite the recent successes of immune checkpoint inhibitors (ICIs) in treating advanced melanoma, durable clinical responses still remain limited. To boost immune responses, agents that target immune regulators, such as the Stimulator of Interferon Genes (STING) agonist cyclic GMP‐AMP (cGAMP), are being investigated. However, their clinical translation is impeded by poor serum stability, rapid tissue clearance, and T‐cell death due to off‐target activation. Recently, a novel strategy termed Microbubble‐assisted UltraSound‐guided Immunotherapy of Cancer (MUSIC) has been reported to selectively deliver cGAMP directly into the cytosol of antigen‐presenting cells with spatiotemporal control. The resulting activation of STING and downstream proinflammatory pathways produces antitumor effects in murine models of breast cancer. Herein, this study reports that MUSIC provides curative results in aggressive murine models of melanoma as well. Under ultrasound exposure, MUSIC reduces tumor size, increases overall survival, and synergizes with ICIs to bridge innate and adaptive immunities. The results from this study represent MUSIC's ability to produce potent immune responses in melanoma, thus indicating its potential as an adjuvant for cancers where ICI is the current standard of care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
- Department of Neurosurgery, MD Anderson Cancer Center, Houston, TX, 77030, USA.
- Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, 77030, USA.
- Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
- Department of Biomedical Engineering, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
ORCID-Profile: Sina Khorsandi, Kristin Huntoon, Betty Y S Kim, Wen Jiang, Jacques Lux
Förderung
- University of Texas Southwestern Medical Center
- U.S. Department of Defense
- American Cancer Society Research Scholar
- Cancer Prevention and Research Institute of Texas
Zitieren
APA
Khorsandi, S., Huntoon, K., Wang, Y., Woodward, A., Antony, A., Endsley, C., Hafeez, N., Edwards, J. L., McCuen, N., Alluri, P. G., Kim, B. Y. S., Jiang, W., & Lux, J. (2025). Targeted STING Activation Using Modified Ultrasound‐Responsive Microbubbles Enhances Immune Checkpoint Blockade Against Melanoma. Advanced Science. https://doi.org/10.1002/advs.202416596
Vancouver
Khorsandi S, Huntoon K, Wang Y, Woodward A, Antony A, Endsley C, et al. Targeted STING Activation Using Modified Ultrasound‐Responsive Microbubbles Enhances Immune Checkpoint Blockade Against Melanoma. Advanced Science. 2025. doi:10.1002/advs.202416596
BibTeX
@article{Khorsandi2025,
author = {Khorsandi, Sina and Huntoon, Kristin and Wang, Yifan and Woodward, Adam and Antony, Abin and Endsley, Connor and Hafeez, Nazia and Edwards, Jared L and McCuen, Nicole and Alluri, Prasanna G and Kim, Betty Y S and Jiang, Wen and Lux, Jacques},
title = {Targeted STING Activation Using Modified Ultrasound‐Responsive Microbubbles Enhances Immune Checkpoint Blockade Against Melanoma},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202416596}
}
EUVIMED